



AACR PATIENT ADVOCATE FORUM

FROM DISCOVERY TO SURVIVORSHIP: TECHNOLOGY'S ROLE IN BEATING CANCER

Speakers

-in order of appearance



GARRY NOLAN, PHD

**Rachford and Carlota Harris Professor
Department of Pathology
Stanford University School of Medicine
Stanford, California**

Dr. Garry Nolan is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. He completed his doctoral training with Leonard Herzenberg and postdoctoral work with Nobel Laureate Dr. David Baltimore, where he contributed to the first cloning and characterization of NF- κ B p65/RelA and developed rapid retroviral production systems. Dr. Nolan has authored over 350 research articles, holds 50 U.S. patents, and has been recognized among Stanford's top 25 inventors. He is the inaugural recipient of the Teal Innovator Award from the Department of Defense and has received multiple grants for advanced studies in immunology and infectious diseases.

Dr. Nolan's research centers on hematopoiesis, cancer, autoimmunity, and computational systems immunology, with a focus on single-cell analysis technologies such as CyTOF and MIBI. He has founded and advised several biotechnology companies and is a member of the Parker Institute for Cancer Immunotherapy. Dr. Nolan's efforts are to enable a deeper understanding not only of normal immune function, trauma, pathogen infection, and other inflammatory events but also detailed substructures of leukemias and solid cancers and their interactions with the immune system—which will enable wholly new understandings that will enable better management of disease and clinical outcomes.



REVA K. BASHO, MD
Chief Medical Officer
Ellison Medical Institute
Los Angeles, CA

Dr. Reva Basho is a breast medical oncologist and an assistant professor of medicine. Prior to the Institute, Dr. Basho served as the Co-Director of the Women's Cancer Research Program at Cedars-Sinai. She received her undergraduate training at Rice University and her medical degree from Baylor College of Medicine. She completed her internal Medicine residency at UCLA Medical Center and her Hematology and Oncology fellowship at MD Anderson Cancer Center.

Alongside her clinical practice, Dr. Basho is a respected and nationally recognized clinical investigator. Her research focuses on the development of novel therapies for the treatment of high-risk breast cancers. Her specific interests include targeting the PI3K pathway and the development of novel immune therapies. She has served as the PI of numerous clinical trials and is currently leading a sub-study of the National Cancer Institute's ComboMATCH trial.



ANGELA M. BELCHER, PHD
James Mason Crafts Professor
Department of Biological Engineering
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, MA

Dr. Angela Belcher is a biological and materials engineer with expertise in the fields of biomaterials, biomolecular materials, organic-inorganic interfaces and solid-state chemistry and devices. Her primary research focus is evolving new materials for energy, electronics, the environment, and medicine. She received her B.S. in Creative Studies from The University of California, Santa Barbara. She earned a Ph.D. in inorganic chemistry at UCSB in 1997. Following her postdoctoral research in electrical engineering at UCSB, she joined the faculty at The University of Texas at Austin in the Department of Chemistry. She joined the faculty at MIT in 2002. In July 2019, she took over as the head of the Biological Engineering Department at MIT through 2023.



CHERYL L. WILLMAN, MD

**The Stephen and Barbara Slaggie Executive Director
Mayo Clinic Cancer Programs and Mayo Clinic Comprehensive Cancer Center
The David A. Ahlquist M.D. Professorship in Cancer Research
Consultant and Professor, Department of Laboratory Medicine and Pathology
Mayo Clinic Alix College of Medicine and Health Sciences
Rochester, Minnesota**

Dr. Cheryl Willman is an internationally renowned physician scientist and a pioneer in the field of cancer individualized medicine with a track record of innovation and successful translation of discoveries to clinical trials. She has co-led several key NCI initiatives that are improving the lives of patients with cancer and addressing disparities in cancer care as well as cancer incidence and mortality among diverse and underserved populations. Dr. Willman has served in many leadership roles including NCI's Board of Scientific Advisors and the Scientific Advisory Board of the NCI Frederick National Laboratory for Cancer Research. Dr. Willman has held and currently holds national leadership positions in AACR, ASH, and the Leukemia and Lymphoma Society. She was a founder of the field of Molecular Diagnostic Pathology, President of the Association of Molecular Pathologists, and is an elected fellow of the National Academy of Inventors. Prior to joining Mayo Clinic, Dr. Willman served as the Director and CEO of the University of New Mexico Comprehensive Cancer Center. Dr. Willman received her medical degree from Mayo Medical School and completed her residency and postdoctoral training in pathology and cancer research at Mayo Clinic, University of New Mexico, and University of Washington.

Moderator



ANNA D. BARKER, PHD, FAACR

**Founder and Chair, AACR Scientist↔Survivor Program®
Chief Strategy Officer, Ellison Medical Institute
Distinguished Visiting Fellow, Complex Adaptive Systems, Arizona State University**

Dr. Barker is the founder and chair of the AACR Scientist↔Survivor Program® and chief strategy officer of the Ellison Medical Institute and distinguished visiting fellow at Arizona State University. She develops information-based strategies through internal research and engagement of networks of leading experts in medicine, science, and engineering to solve complex problems in cancer and other diseases. Previously, Dr. Barker served as the principal deputy director of the National Cancer Institute (NCI) where she led the development of Foundational platforms (Clinical Proteomics and National Cancer Nanotechnology Centers) and national programs (e.g., TCGA, Physical-Sciences Oncology Centers) to support the emerging concept of precision medicine. Hallmarks of these strategic innovative programs were networks of global institutions, team science and publicly available data.

Post NCI, Dr. Barker served as director of Transformative Healthcare Networks, co-director of Complex Adaptive Systems -Biomedicine (CAS) and professor of practice, School of Life Sciences at Arizona State University (ASU), where she maintains a courtesy academic appointment. At ASU, she employed CAS approaches through “knowledge networks” to enable progress in areas ranging from clinical trial designs

to biomarker discovery and applying concepts from the physical sciences to fundamentally understand and control complex diseases such as cancer.

Dr. Barker also spent several years at Battelle Memorial Institute, a nonprofit transdisciplinary research organization, where she progressed from a research scientist to serve in several senior executive roles. She has received numerous awards for her contributions to cancer research, cancer patients and patient advocates, professional organizations, and the ongoing national effort to prevent and cure cancer. Dr. Barker received her doctoral degree from Ohio State University.